We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Prospective Analysis Of Cardiac Function In Cirrhotic Patients By Echocardiography And Its Correlation With Events

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01433848
Recruitment Status : Unknown
Verified September 2011 by Angelo Antunes Salgado, Rio de Janeiro State University.
Recruitment status was:  Enrolling by invitation
First Posted : September 14, 2011
Last Update Posted : September 14, 2011
Information provided by (Responsible Party):

Study Description
Brief Summary:

The cardiac abnormalities in patients with cirrhosis are already reported from the 50's, in studies of patients with alcoholic cirrhosis. Further studies have shown that these cardiac changes were caused not only by the myotoxic effects of alcohol, but also are present in many patients regardless of etiology of cirrhosis.

These changes are characterized by abnormalities of systolic contraction in patients undergoing physical or pharmacological stress, changes in diastolic function and electrophysiological changes in a clinical condition known as cirrhotic cardiomyopathy. Increased QT interval and the pre-ejection time changes are common in cirrhotic patients.

To date no studies have evaluated the clinical relevance of changes in the heart of cirrhotic patients, or their relationship with the prognosis of affected patients. Til now, researches are based on strict echocardiographic parameters, not including several modern methods of assessment of cardiac systole and diastole. New techniques, such as two-dimensional strain, can bring new diagnostic and prognostic information, and it is not reported in the literature. Therefore, the aim of this study is to determine the morphological and functional cardiac changes in patients with cirrhosis and their prognostic role by evaluating new echocardiographic parameters of systolic and diastolic readings.

Condition or disease
Liver Cirrhosis

Study Design

Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Prospective Analysis Of Cardiac Function In Cirrhotic Patients By Echocardiography And Its Correlation With Adverse Events
Study Start Date : June 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cirrhosis
U.S. FDA Resources

Groups and Cohorts

Child A liver cirrhosis
Child B liver cirrhosis
Child C liver cirrhosis

Outcome Measures

Primary Outcome Measures :
  1. Adverse events as defined as composite of death due to liver failure, gastrointestinal bleeding, spontaneous bacterial peritonitis or need to conduct liver transplant in patients with liver cirrhosis. [ Time Frame: 12 months follow-up ]

    Identify the occurrence of adverse events as defined as:

    1. death due to liver failure, characterized by development of severe liver injury with impaired synthetic function and encephalopathy in a person who previously had well-compensated liver disease.
    2. either upper or lower gastrointestinal bleeding, characterized by hematemesis (vomiting of blood or coffee-ground like material) and/or melena (black, tarry stools).
    3. spontaneous bacterial peritonitis, characterized by as an ascitic fluid infection without an evident intraabdominal surgically-treatable source.
    4. liver transplant.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Will be selected patients with cirrhosis (diagnosed by clinical criteria and ultrasound and / or liver biopsy) at different evolutionary stages os disease in the hepatology`s service at the University Hospital Pedro Ernesto.

Inclusion Criteria:

  • Patients with cirrhosis of any etiology, diagnosed by clinical criteria and ultrasound and / or liver biopsy, which excluded patients with causes that also may affect cardiac function (hemochromatosis, Wilson disease, amyloidosis).
  • Age between 18 and 80 years.
  • Signing of written informed consent.

Exclusion Criteria:

  • History or presence of systemic arterial hypertension (treated or not)
  • History or presence of ischemic heart disease and peripheral vascular disease.
  • Presence of greater than mild valvular disease.
  • Patients who have a different rhythm in the baseline electrocardiogram, other than sinus (atrial fibrillation, atrial flutter, junctional rhythm).
  • Presence of severe anemia (Hb <7 g / dL).
  • Presence of shock, hepatic encephalopathy, bacterial infection or bleeding at inclusion or during the previous week.
  • History or presence of severe or decompensated lung disease.
  • Presence of percutaneous intrahepatic porto-systemic shunt (TIPS).
  • Pregnancy.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01433848

Universidade do Estado do Rio de Janeiro
Rio de Janeiro, RJ, Brazil, 20551030
Sponsors and Collaborators
Rio de Janeiro State University
Principal Investigator: Angelo A Salgado, Master Rio de Janeiro State University
Study Chair: Carlos Terra, PHD Rio de Janeiro State University
Study Chair: Márcia B Castier, PHD Rio de Janeiro State University
Study Chair: Paulo R Benchimol-Barbosa, DSC Rio de Janeiro State University
Principal Investigator: Camila SS Reis, MD Universidade de Estado do Rio de Janeiro
More Information

Responsible Party: Angelo Antunes Salgado, Clinical practitioner, Rio de Janeiro State University
ClinicalTrials.gov Identifier: NCT01433848     History of Changes
Other Study ID Numbers: arquivo1
First Posted: September 14, 2011    Key Record Dates
Last Update Posted: September 14, 2011
Last Verified: September 2011

Additional relevant MeSH terms:
Liver Cirrhosis
Liver Diseases
Digestive System Diseases